RESUMEN
Chemotherapy is still one of the main therapeutic approaches in cancer therapy. Nevertheless, its poor selectivity causes severe toxic side effects that, together with the development of drug resistance in tumor cells, results in a limitation for its application. Tumor-targeted drug delivery is a possible choice to overcome these drawbacks. As well as monoclonal antibodies, peptides are promising targeting moieties for drug delivery. However, the development of peptide-drug conjugates (PDCs) is still a big challenge. The main reason is that the conjugates have to be stable in circulation, but the drug or its active metabolite should be released efficiently in the tumor cells. For this purpose, suitable linker systems are needed that connect the drug molecule with the homing peptide. The applied linker systems are commonly categorized as cleavable and non-cleavable linkers. Both the groups possess advantages and disadvantages that are summarized briefly in this manuscript. Moreover, in this review paper, we highlight the benefit of oxime-linked anthracycline-peptide conjugates in the development of PDCs. For instance, straightforward synthesis as well as a conjugation reaction proceed in excellent yields, and the autofluorescence of anthracyclines provides a good tool to select the appropriate homing peptides. Furthermore, we demonstrate that these conjugates can be used properly in in vivo studies. The results indicate that the oxime-linked PDCs are potential candidates for targeted tumor therapy.
Asunto(s)
Antineoplásicos , Neoplasias , Humanos , Daunorrubicina/uso terapéutico , Antineoplásicos/farmacología , Antineoplásicos/uso terapéutico , Oximas/uso terapéutico , Péptidos/química , Neoplasias/tratamiento farmacológico , Neoplasias/metabolismo , Sistemas de Liberación de Medicamentos/métodos , Preparaciones Farmacéuticas/metabolismoRESUMEN
Self-assembling peptides are attractive alternatives in the field of biomaterial science due to their variability and biocompatibility. Unfortunately, such peptides have poor solubility, and their purification, synthesis, and overall handling are challenging. Our main objective was to develop a cage peptide design with full control over self-assembly. Theoretically, aggregation can be suppressed by temporally masking the amino acid side chains at critical positions. Taking into account several biological and synthetic requirements, a photosensitive protecting group, p-hydroxy-phenacyl (pHP), was chosen as the "masking" moiety. To test our theory, EAK16-II was chosen as a model self-assembling peptide, and a caged derivative containing photosensitive pHP groups was synthesized. Both spectroscopic and in vitro experiments on A2058 melanoma cells confirmed our hypothesis that the caged-EAK16-II peptide has good solubility and that the hydrogel formed after photolysis results in similar viability and cell aggregate formation of melanoma cells as the native EAK16-II-based hydrogel.
RESUMEN
Pancreatic adenocarcinoma is one of the tumours with the worst prognosis, with a 5-year survival rate of 5-10%. Our aim was to find and optimise peptide-based drug conjugates with daunorubicin (Dau) as the cytotoxic antitumour agent. When conjugated with targeting peptides, the side effect profile and pharmacokinetics of Dau can be improved. The targeting peptide sequences (e.g. GSSEQLYL) we studied were originally selected by phage display. By Ala-scan technique, we identified that position 6 in the parental sequence (Dau=Aoa-LRRY-GSSEQLYL-NH2, ConjA) could be modified without the loss of antitumour activity (Dau=Aoa-LRRY-GSSEQAYL-NH2, Conj03: 14. 9% viability). Our results showed that the incorporation of p-chloro-phenylalanine (Dau=Aoa-LRRY-GSSEQF(pCl)YL-NH2, Conj16) further increased the antitumour potency (10-5 M: 9.7% viability) on pancreatic adenocarcinoma cells (PANC-1). We found that conjugates containing modified GSSEQLYL sequences could be internalised to PANC-1 cells and induce cellular senescence in the short term and subsequent apoptotic cell death. Furthermore, the cardiotoxic effect of Dau was markedly reduced in the form of peptide conjugates. In conclusion, Conj16 had the most effective antitumor activity on PANC-1 cells, which makes this conjugate promising for developing new targeted therapies without cardiotoxic effects.